<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33880442</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-9090</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of translational autoimmunity</Title><ISOAbbreviation>J Transl Autoimmun</ISOAbbreviation></Journal><ArticleTitle>Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.</ArticleTitle><Pagination><StartPage>100100</StartPage><MedlinePgn>100100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100100</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtauto.2021.100100</ELocationID><Abstract><AbstractText>Impairment of health after overcoming the acute phase of COVID-19 is being observed more and more frequently. Here different symptoms of neurological and/or cardiological origin have been reported. With symptoms, which are very similar to the ones reported but are not caused by SARS-CoV-2, the occurrence of functionally active autoantibodies (<sub>f</sub>AABs) targeting G-protein coupled receptors (GPCR-<sub>f</sub>AABs) has been discussed to be involved. We, therefore investigated, whether GPCR-<sub>f</sub>AABs are detectable in 31 patients suffering from different Long-COVID-19 symptoms after recovery from the acute phase of the disease. The spectrum of symptoms was mostly of neurological origin (29/31 patients), including post-COVID-19 fatigue, alopecia, attention deficit, tremor and others. Combined neurological and cardiovascular disorders were reported in 17 of the 31 patients. Two recovered COVID-19 patients were free of follow-up symptoms. All 31 former COVID-19 patients had between 2 and 7 different GPCR-<sub>f</sub>AABs that acted as receptor agonists. Some of those GPCR-<sub>f</sub>AABs activate their target receptors which cause a positive chronotropic effect in neonatal rat cardiomyocytes, the read-out in the test system for their detection (bioassay for GPCR-<sub>f</sub>AAB detection). Other GPCR-<sub>f</sub>AABs, in opposite, cause a negative chronotropic effect on those cells. The positive chronotropic GPCR-<sub>f</sub>AABs identified in the blood of Long-COVID patients targeted the &#x3b2;<sub>2</sub>-adrenoceptor (&#x3b2;<sub>2</sub>-<sub>f</sub>AAB), the &#x3b1;<sub>1</sub>-adrenoceptor (&#x3b1;<sub>1</sub>-<sub>f</sub>AAB), the angiotensin II AT1-receptor (AT1-<sub>f</sub>AAB), and the nociceptin-like opioid receptor (NOC-<sub>f</sub>AAB). The negative chronotropic GPCR-<sub>f</sub>AABs identified targeted the muscarinic M<sub>2</sub>-receptor (M<sub>2</sub>-<sub>f</sub>AAB), the MAS-receptor (MAS-<sub>f</sub>AAB), and the ETA-receptor (ETA-<sub>f</sub>AAB). It was analysed which of the extracellular receptor loops was targeted by the autoantibodies.</AbstractText><CopyrightInformation>&#xa9; 2021 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wallukat</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Research Center, Charit&#xe9; Campus Buch, Max-Delbr&#xfc;ck Center for Molecular Medicine, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohberger</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Erlangen, Friedrich-Alexander-University of Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xfc;rst</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze-Rothe</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallukat</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;nicke</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin; Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Transl Autoimmun</MedlineTA><NlmUniqueID>101759413</NlmUniqueID><ISSNLinking>2589-9090</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2, Angiotensin-converting enzyme 2 receptors</Keyword><Keyword MajorTopicYN="N">AT1-fAAB, Autoantibody targeting the angiotensin II AT1 receptor</Keyword><Keyword MajorTopicYN="N">Autoantibody</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CRPS, Complex regional pain syndrome</Keyword><Keyword MajorTopicYN="N">ETA-fAAB, Autoantibody targeting the endothelin receptor</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">GPCR, G-protein coupled receptors</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">M2-fAAB, Autoantibody targeting the muscarinic receptor</Keyword><Keyword MajorTopicYN="N">MAS-fAAB, Autoantibody targeting the MAS receptor</Keyword><Keyword MajorTopicYN="N">NOC-fAAB, Functionally active autoantibody against the nociceptin receptor</Keyword><Keyword MajorTopicYN="N">PoTS, Postural orthostatic tachycardia syndrome</Keyword><Keyword MajorTopicYN="N">Post-covid-19 symptom</Keyword><Keyword MajorTopicYN="N">RAS, Renin angiotensin system</Keyword><Keyword MajorTopicYN="N">SARS, Severe acute respiratory syndrome</Keyword><Keyword MajorTopicYN="N">fAAB, Functional autoantibody</Keyword><Keyword MajorTopicYN="N">&#x3b1;1-fAAB, Autoantibody targeting the alpha1-adrenoceptor</Keyword><Keyword MajorTopicYN="N">&#x3b2;2-fAAB, Autoantibody targeting the beta2-adrenoceptor</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. G. Wallukat, K. Wenzel, S. Schulze-Rothe, A. Wallukat, A.S. H&#xf6;nicke, and J. M&#xfc;ller are employed by the Berlin Cures GmbH. G. Wallukat and J. M&#xfc;ller are shareholders of the Berlin Cures Holding AG, the holding company of Berlin Cures. The authors declare no competing interests. All other authors have nothing to declare. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject or materials discussed in the manuscript apart from those which are disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33880442</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pii">S2589-9090(21)00020-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. J.&#xa0;Am. Med. Assoc. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603. Gemelli Against COVID-19 Post-Acute Care Study Group.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Munz M., Wessendorf S., Koretsis G. Acute transverse myelitis after COVID-19 pneumonia. J.&#xa0;Neurol. 2020;267:2196&#x2013;2197. doi: 10.1007/s00415-020-09934-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09934-w</ArticleId><ArticleId IdType="pmc">PMC7250275</ArticleId><ArticleId IdType="pubmed">32458198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow C.C.N., Magnussen J., Ip J., Su Y. Acute transverse myelitis in COVID-19 infection. BMJ Case Rep. 2020;13(8) doi: 10.1136/bcr-2020-236720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-236720</ArticleId><ArticleId IdType="pmc">PMC7418849</ArticleId><ArticleId IdType="pubmed">32784242</ArticleId></ArticleIdList></Reference><Reference><Citation>Maideniuc C., Memon A.B. Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient. J.&#xa0;Neurol. 2020;9:1&#x2013;3. doi: 10.1007/s00415-020-10145-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10145-6</ArticleId><ArticleId IdType="pmc">PMC7415129</ArticleId><ArticleId IdType="pubmed">32772172</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano G., Palmerini F., Ravaglia S. Guillain&#x2013;barr&#xe9; syndrome associated with SARS-CoV-2. N.&#xa0;Engl. J. Med. 2020;382(26):2574&#x2013;2576.. doi: 10.1056/NEJMc2009191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009191</ArticleId><ArticleId IdType="pmc">PMC7182017</ArticleId><ArticleId IdType="pubmed">32302082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachariadis A., Tulbu A., Strambo D. Transverse myelitis related to COVID-19 infection. J.&#xa0;Neurol. Dec 2020;267(12):3459&#x2013;3461. doi: 10.1007/s00415-020-09997-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09997-9</ArticleId><ArticleId IdType="pmc">PMC7322383</ArticleId><ArticleId IdType="pubmed">32601756</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuccio F.G., Barra M., Claudio G., Claudio S. A&#xa0;rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection. J.&#xa0;Neurol. 2020;17:1&#x2013;4. doi: 10.1007/s00415-020-10219-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10219-5</ArticleId><ArticleId IdType="pmc">PMC7497229</ArticleId><ArticleId IdType="pubmed">32940797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty U., Chandra A., Ray A.K., Biswas P. COVID-19-associated acute transverse myelitis: a rare entity. BMJ Case Rep. 2020;13(8) doi: 10.1136/bcr-2020-238668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-238668</ArticleId><ArticleId IdType="pmc">PMC7449353</ArticleId><ArticleId IdType="pubmed">32843475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur H., Mason J.A., Bajracharya M. Transverse myelitis in a child with COVID-19. Pediatr. Neurol. 2020;112:5&#x2013;6. doi: 10.1016/j.pediatrneurol.2020.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.07.017</ArticleId><ArticleId IdType="pmc">PMC7388012</ArticleId><ArticleId IdType="pubmed">32823138</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Carerj M.L., Wieters I. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265&#x2013;1273. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:811&#x2013;818. doi: 10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner D., Fitzek A., Br&#xe4;uninger H. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281&#x2013;1285. doi: 10.1001/jamacardio.2020.3551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3551</ArticleId><ArticleId IdType="pmc">PMC7385672</ArticleId><ArticleId IdType="pubmed">32730555</ArticleId></ArticleIdList></Reference><Reference><Citation>Driggin E., Madhavan M.V., Bikdeli B. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J.&#xa0;Am. Coll. Cardiol. 2020;75:2352&#x2013;2371. doi: 10.1016/j.jacc.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7198856</ArticleId><ArticleId IdType="pubmed">32201335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M., Wang D.W., Han Y. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17:543&#x2013;558. doi: 10.1038/s41569-020-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaratunga E.A., Corwin D.S., Moran L., Snyder R. Bradycardia in patients with COVID-19: a calm before the storm? Cureus. 2020;12 doi: 10.7759/cureus.8599.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8599</ArticleId><ArticleId IdType="pmc">PMC7294893</ArticleId><ArticleId IdType="pubmed">32550090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M.D., Qamar A., Mp G. Bradyarrhythmias in patients with COVID-19: a case series. Indian Pacing Electrophysiol. J. 2020;20:211&#x2013;212. doi: 10.1016/j.ipej.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ipej.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7434619</ArticleId><ArticleId IdType="pubmed">32822746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashok V., Loke W.I. Case report: high-grade atrioventricular block in suspected COVID-19 myocarditis. Eur. Heart J. Case Rep. 2020;4:1&#x2013;6. doi: 10.1093/ehjcr/ytaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytaa248</ArticleId><ArticleId IdType="pmc">PMC7499545</ArticleId><ArticleId IdType="pubmed">33089060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kir D., Mohan C., Sancassani R. Heart brake: an unusual cardiac manifestation of COVID-19. JACC Case Rep. 2020;2:1252&#x2013;1255. doi: 10.1016/j.jaccas.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7196413</ArticleId><ArticleId IdType="pubmed">32368756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayek S.S., Brenner S.K., Azam T.U. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020;371:m3513. doi: 10.1136/bmj.m3513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3513</ArticleId><ArticleId IdType="pmc">PMC7525342</ArticleId><ArticleId IdType="pubmed">32998872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Han T., Chen J. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin. Transl. Sci. 2020;13(6):1077&#x2013;1086. doi: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M., Tincani A., Andreoli L. Covid-19 and autoimmunity. Autoimmun. Rev. 2020;19:102597. doi: 10.1016/j.autrev.2020.102597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102597</ArticleId><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J. vol. 12. medRxiv 2020; 2020. Diverse Functional Autoantibodies in Patients with COVID-19. 10.20247205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.10.20247205</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515) doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L., Motta F., De Santis M. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - a systematic review of the literature. J.&#xa0;Autoimmun. 2020;117 doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J.&#xa0;Transl. Autoimmun. 2020;3 doi: 10.1016/j.jtauto.2020.100051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100051</ArticleId><ArticleId IdType="pmc">PMC7142689</ArticleId><ArticleId IdType="pubmed">32292901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreye J., Reincke S.M., Kornau H.-C. A&#xa0;therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183:1058&#x2013;1069. doi: 10.1016/j.cell.2020.09.049. e19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.049</ArticleId><ArticleId IdType="pmc">PMC7510528</ArticleId><ArticleId IdType="pubmed">33058755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature. 2021;590(7844):29&#x2013;31. doi: 10.1038/d41586-021-00149-1. https://www.nature.com/articles/d41586-021-00149-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00149-1</ArticleId><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y., Ryabkova V.A., Scheibenbogen C. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin. Immunol. 2020;214:108384. doi: 10.1016/j.clim.2020.108384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108384</ArticleId><ArticleId IdType="pubmed">32171889</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C., Loebel M., Freitag H. Immunoadsorption to remove &#xdf;2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS One. 2018;13 doi: 10.1371/journal.pone.0193672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193672</ArticleId><ArticleId IdType="pmc">PMC5854315</ArticleId><ArticleId IdType="pubmed">29543914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Pr&#xfc;ss H., M&#xfc;ller J., Schimke I. Functional autoantibodies in patients with different forms of dementia. PLoS One. 2018;13 doi: 10.1371/journal.pone.0192778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192778</ArticleId><ArticleId IdType="pmc">PMC5851545</ArticleId><ArticleId IdType="pubmed">29538413</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;ngen H.-D., Dordevic A., Felix S.B. &#x3b2;1-Adrenoreceptor autoantibodies in heart failure: physiology and therapeutic implications. Circ. Heart Fail. 2020;13 doi: 10.1161/CIRCHEARTFAILURE.119.006155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.006155</ArticleId><ArticleId IdType="pubmed">31957469</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris P.A., Taylor R., Thielke R. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J.&#xa0;Biomed. Inf. 2009;42:377&#x2013;381. doi: 10.1016/j.jbi.2008.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Davideit H., Haberland A., Bartel S. Determination of agonistically acting autoantibodies to the adrenergic beta-1 receptor by cellular bioassay. Methods Mol. Biol. 2019;1901:95&#x2013;102. doi: 10.1007/978-1-4939-8949-2_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-8949-2_8</ArticleId><ArticleId IdType="pubmed">30539571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel K., Schulze-Rothe S., Haberland A. Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathy. Heliyon. 2017;3 doi: 10.1016/j.heliyon.2017.e00362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2017.e00362</ArticleId><ArticleId IdType="pmc">PMC5541141</ArticleId><ArticleId IdType="pubmed">28795160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Wenzel K., Schimke I. Analytics of functional autoantibodies in patients with chagas disease. Methods Mol. Biol. 2019;1955:247&#x2013;261. doi: 10.1007/978-1-4939-9148-8_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9148-8_19</ArticleId><ArticleId IdType="pubmed">30868533</ArticleId></ArticleIdList></Reference><Reference><Citation>Orjatsalo M., Partinen E., Wallukat G. Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1. Sleep Med. 2020;77:82&#x2013;87. doi: 10.1016/j.sleep.2020.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2020.11.038</ArticleId><ArticleId IdType="pubmed">33341642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Jandrig B., Becker N.-P. Autoantibodies directed against &#x3b1;1-adrenergic receptor and endothelin receptor A in patients with prostate cancer. Auto Immun. Highlights. 2020;11:13. doi: 10.1186/s13317-020-00136-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13317-020-00136-y</ArticleId><ArticleId IdType="pmc">PMC7519497</ArticleId><ArticleId IdType="pubmed">32977857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., Kunze R., Wallukat G. Autoantibodies activating the &#x3b2;2-adrenergic receptor characterize patients with primary and secondary glaucoma. Front. Immunol. 2019;10:2112. doi: 10.3389/fimmu.2019.02112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02112</ArticleId><ArticleId IdType="pmc">PMC6779694</ArticleId><ArticleId IdType="pubmed">31632387</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M., Grabowski P., Heidecke H. Antibodies to &#x3b2; adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav. Immun. 2016;52:32&#x2013;39. doi: 10.1016/j.bbi.2015.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.09.013</ArticleId><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharraziha I., Axelsson J., Ricci F. Serum activity against G protein-coupled receptors and severity of orthostatic symptoms in postural orthostatic tachycardia syndrome. J.&#xa0;Am. Heart Assoc. 2020;9 doi: 10.1161/JAHA.120.015989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.015989</ArticleId><ArticleId IdType="pmc">PMC7792263</ArticleId><ArticleId IdType="pubmed">32750291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohr D., Singh P., Tschernatsch M. Autoimmunity against the &#x3b2;2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain. 2011;152:2690&#x2013;2700. doi: 10.1016/j.pain.2011.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2011.06.012</ArticleId><ArticleId IdType="pubmed">21816540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M.L., Herlitz H., Schulze W. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J.&#xa0;Hypertens. 2000;18:945&#x2013;953. doi: 10.1097/00004872-200018070-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004872-200018070-00017</ArticleId><ArticleId IdType="pubmed">10930193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Neichel D., Nissen E. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can. J. Physiol. Pharmacol. 2003;81:79&#x2013;83. doi: 10.1139/y02-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y02-160</ArticleId><ArticleId IdType="pubmed">12710518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragun D., M&#xfc;ller D.N., Br&#xe4;sen J.H. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N.&#xa0;Engl. J. Med. 2005;352:558&#x2013;569. doi: 10.1056/NEJMoa035717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035717</ArticleId><ArticleId IdType="pubmed">15703421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukitsch I., Kehr J., Chaykovska L. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation. 2012;94:8&#x2013;13. doi: 10.1097/TP.0b013e3182529bb7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3182529bb7</ArticleId><ArticleId IdType="pubmed">22691955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremer S., Jakob C., Berkowitsch A. Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clin. Res. Cardiol. 2020;19:1&#x2013;12. doi: 10.1007/s00392-020-01769-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01769-9</ArticleId><ArticleId IdType="pmc">PMC7674577</ArticleId><ArticleId IdType="pubmed">33211155</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouladseresht H., Doroudchi M., Rokhtabnak N. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. Cytokine Growth Factor Rev. 2020;58:32&#x2013;48. doi: 10.1016/j.cytogfr.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7544568</ArticleId><ArticleId IdType="pubmed">33199179</ArticleId></ArticleIdList></Reference><Reference><Citation>Okruhlicova L., Morwinski R., Schulze W. Autoantibodies against G-protein-coupled receptors modulate heart mast cells. Cell. Mol. Immunol. 2007;4:127&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484807</ArticleId></ArticleIdList></Reference><Reference><Citation>Steckelings U.M., Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin. Sci. (Lond.) 2020;134:2987&#x2013;3006. doi: 10.1042/CS20200922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200922</ArticleId><ArticleId IdType="pubmed">33210709</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland A., Santos R.A.S., Schimke I., Wallukat G. Are agonistic autoantibodies against G-protein coupled receptors involved in the development of long-term side effects of tumor chemotherapy? Case Rep. Oncol. 2013;6:104&#x2013;108. doi: 10.1159/000348425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000348425</ArticleId><ArticleId IdType="pmc">PMC3618042</ArticleId><ArticleId IdType="pubmed">23569443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Morwinski M., Kowal K. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization. Eur. Heart J. 1991;12 doi: 10.1093/eurheartj/12.suppl_d.178. Suppl D:178&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/12.suppl_d.178</ArticleId><ArticleId IdType="pubmed">1717272</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandel M., Wallukat G., Englert A. Long-term benefits of immunoadsorption in &#x3b2;(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur. J. Heart Fail. 2012;14:1374&#x2013;1388. doi: 10.1093/eurjhf/hfs123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfs123</ArticleId><ArticleId IdType="pubmed">22892122</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J., Wallukat G., Dandel M. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653829</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;nemann A., Hohberger B., Rech J. Agonistic autoantibodies to the &#x3b2;2-adrenergic receptor involved in the pathogenesis of open-angle glaucoma. Front. Immunol. 2018;9:145. doi: 10.3389/fimmu.2018.00145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00145</ArticleId><ArticleId IdType="pmc">PMC5816038</ArticleId><ArticleId IdType="pubmed">29483909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>